BDR Pharma to launch 80mg of Enzalutamide for treatment of Prostate Cancer in India Kumar Jeetendra | September 21, 2020 Mumbai 21st September 2020: BDR Pharmaceutical today announces the launch of 80mg advanced version of its Enzalutamide drug. BDR Pharma had earlier received approval from the Drugs Controller General of India (DCGI) to manufacture 40mg Enzalutamide in 2017 to treat men with metastatic castration-resistant prostate cancer (mCRPC) under the brand name BDENZA. The 80 mg …
Aurobindo Pharma ties up with BIRAC to create COVID-19 immunization Kumar Jeetendra | September 17, 2020 Aurobindo Pharma on Tuesday announced collaboration with the Biotechnology Industry Research Assistance Council (BIRAC), set up by the Department of Biotechnology for the development of COVID-19 vaccine. Aurobindo Pharma said it is developing a vaccine for COVID-19 through its wholly-owned US subsidiary, Auro Vaccines. “Aurobindo is in the process of preparing a state-of-art manufacturing facility …
Dr Reddy’s’ settles case with Bristol Myers Squibb unit over nonexclusive malignant growth drug Kumar Jeetendra | September 17, 2020 The Hyderabad-based firm has settled litigation with Celgene, a wholly-owned subsidiary of Bristol Myers Squibb, Dr Reddy”s Laboratories said in a statement. In settlement of all outstanding claims in the litigation, Celgene has agreed to provide the company with a permit to sell volume-limited amounts of generic lenalidomide capsules in america starting on a confidential …
Dr Reddy’s accomplices with RDIF to convey 100 million doses of Sputnik V antibody in India Kumar Jeetendra | September 16, 2020 Hyderabad, Sep 16 (PTI) The Russian Direct Investment Fund (RDIF), Russias autonomous wealth finance, and Dr Reddys Laboratories Ltd. have agreed to collaborate on clinical trials and supply of Sputnik V vaccine in India. Upon regulatory approval in India, RDIF shall supply to Dr. Reddys 100 million doses of the vaccine, Dr Reddys stated in …
Aurobindo Pharma ties up with BIRAC to create COVID-19 antibody Kumar Jeetendra | September 15, 2020 Aurobindo Pharma on Tuesday announced collaboration with the Biotechnology Industry Research Assistance Council (BIRAC), set up by the Department of Biotechnology for the development of COVID-19 vaccine. BIRAC has facilitated the establishment of’the r-VSV vaccine’ manufacturing platform for the first time in India by encouraging Aurobindo Pharma’s COVID-19 vaccine development, the company said in a …
Merck begins enrollment for COVID-19 vaccine preliminary Kumar Jeetendra | September 12, 2020 United States drugmaker Merck & Co Inc has begun recruiting participants into its early-stage COVID-19 vaccine study, according to the government database clinicaltrials.gov. The phase 1/2 trial, which is based in Belgium, intends to recruit 260 healthy participants to check the experimental vaccine V591, which it gained access to as a member of its May …
Zydus Cadila gets USFDA gesture to showcase its disease treatment infusion Kumar Jeetendra | September 11, 2020 New Delhi, Sep 11 (PTI) Medication firm Zydus Cadila on Friday said it has received final nod in the US health regulator to advertise its generic Doxorubicin Hydrochloride Liposome injection, used for treatment of certain types of cancer, in the American market. The company has received final approval from the United States Food and Drug …
Granules India arm gets USFDA gesture for ADHD treatment drug Kumar Jeetendra | September 11, 2020 New Delhi, Sep 11 (PTI) Medication firm Granules India Friday said its subsidiary has received marketing approval from the US health regulator for Dexmethylphenidate HCl extended-release capsules, used for the treatment of attention-deficit hyperactivity disorder (ADHD). The approved product is bioequivalent to the reference listed drug Focalin XR of Novartis AG. In a BSE filing, …
RedHill Biopharma’s Opaganib Demonstrates Complete Inhibition of SARS-CoV-2 Kumar Jeetendra | September 8, 2020 TEL AVIV, Israel and RALEIGH, N.C., Sept. 08, 2020 (GLOBE NEWSWIRE) — RedHill Biopharma Ltd. (Nasdaq: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company, today announced that opaganib1 demonstrated potent inhibition of SARS-CoV-2, the virus that causes COVID-19, achieving complete blockage of viral replication in an in vitro model of human lung bronchial tissue. …
Protein-based COVID-19 vaccine trial launched by Sanofi and GSK Kumar Jeetendra | September 3, 2020 French drugmaker Sanofi and its British peer GSK have begun a clinical trial for a protein-based COVID-19 vaccine candidate, as pharmaceutical firms race to develop treatments against the coronavirus pandemic. Sanofi and GSK said in a joint statement on Thursday they’d begun the”Stage 1/2″ trial for their adjuvanted COVID-19 vaccine, and that they expect to …
Lupin dispatches generic rheumatoid arthritis drug in US market Kumar Jeetendra | September 2, 2020 Medicine manufacturer Lupin on Wednesday said it has established Leflunomide pills, used to treat rheumatoid arthritis, even in the US marketplace. The business has established the product in 10 mg and 20 mg strengths after receiving the approval by the US Food and Drug Administration (USFDA) before, Lupin said in a statement. The item could …
Zydus Cadila gets USFDA gesture for muscle relaxant infusion Kumar Jeetendra | September 2, 2020 Zydus Cadila has obtained final acceptance by the US Food and Drug Administration (USFDA) to advertise Cisatracurium Besylate Injection USP at the potency of 20 milligrams (base)/10 mL (two mg/mL) multiple-dose vial, Cadila Healthcare stated in a regulatory filing on Wednesday. The drug will be produced in Liva plant of Cadila Healthcare Ltd.. Zydus Cadila …
